BioPharma Dive January 11, 2022
The second day of the J.P. Morgan Healthcare Conference, much like the first, didn’t include the type of market-moving acquisitions or announcements that might break the biopharmaceutical sector out of its slump.
But anticipation for such a move is high, with nearly every large drugmaker fielding questions from analysts and investors about what they aim to do with all the cash at their disposal.
Executives didn’t give much away, but their answers reflect how biotech has changed in recent years, with an explosion of new companies giving big pharma more opportunities to spread their bets.
Read on for details on what they said, as well as for some other notable updates from the meeting:
How big is a...
Today's Sponsors
Today's Sponsor